These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Completed, but no date||2009-009315-22||A randomized phase II study of erlotinib compared to single agent chemotherapy-erlotinib combination in pretreated patients with advanced NSCLC (NVALT10 study)||bad-data|
|Ongoing||2010-022104-50||A randomized phase II study of paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in patients with stage IV non-squamous-non-small cell lung cancer: NVALT12||not-yet-due|
|Ongoing||2012-005272-34||Iressa RE-challenge in advanced NSCLC EGFR mutated patients who responded to an EGFR-TKI used as first-line or previous treatment. Het opnieuw geven van Iressa in EGFR-gemuteerde patienten die ree...||not-yet-due|
|Ongoing||2012-005834-12||Switch maintenance treatment with gemcitabine for patients with malignant mesothelioma who do not progress after 1st line therapy with a pemetrexed-platinum combination. A randomised open label phase ...||not-yet-due|
|Ongoing||2013-002050-78||A Phase III, randomised trial of adding nitroglycerin to first line chemotherapy for advanced nonsmall cell lung cancer||not-yet-due|
|Ongoing||2013-004303-39||A randomized phase III study of erlotinib compared to intercalated erlotinib with cisplatinum pemetrexed as first-line therapy for advanced EGFR mutated non-small-cell lung cancer. The NVALT17 study||not-yet-due|
|Listed as ongoing, but also has a completion date||2013-004324-11||Phase II study with oral fibroblast growth factor-1 inhibitor BIBF1120 as second line treatment in lung carcinoma patients harboring fibroblast growth factor receptor-1 gene amplification (NVALT-15 st...||2019-01-15||bad-data|
|Ongoing||2015-003121-34||Chemotherapy in KRAS mutated chemotherapy naive non-small cell lung cancer patients: a phase III study comparing cisplatin-pemetrexed with carboplatin-paclitaxel-bevacizumab: NVALT 22||not-yet-due|
|Ongoing||2018-001781-41||Evaluation of safety and tolerability of pirfenidone in asbestosis, a multicenter study Evaluatie van de veiligheid en tolerantie van Pirfenidone bij asbestose, een multicenter studie||not-yet-due|